BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 11815296)

  • 1. The LMP2A signalosome--a therapeutic target for Epstein-Barr virus latency and associated disease.
    Portis T; Cooper L; Dennis P; Longnecker R
    Front Biosci; 2002 Feb; 7():d414-26. PubMed ID: 11815296
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of host kinase activity altered by the LMP2A signalosome-a therapeutic target for Epstein-Barr virus latency and associated disease.
    Cooper L; Longnecker R
    Antiviral Res; 2002 Dec; 56(3):219-31. PubMed ID: 12406506
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of latent membrane protein 2 isoforms in Epstein-Barr virus latency.
    Rechsteiner MP; Bernasconi M; Berger C; Nadal D
    Trends Microbiol; 2008 Nov; 16(11):520-7. PubMed ID: 18835714
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epstein-Barr virus LMP2A increases IL-10 production in mitogen-stimulated primary B-cells and B-cell lymphomas.
    Incrocci R; McCormack M; Swanson-Mungerson M
    J Gen Virol; 2013 May; 94(Pt 5):1127-1133. PubMed ID: 23303827
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epstein-Barr virus (EBV) LMP2A mediates B-lymphocyte survival through constitutive activation of the Ras/PI3K/Akt pathway.
    Portis T; Longnecker R
    Oncogene; 2004 Nov; 23(53):8619-28. PubMed ID: 15361852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The signaling pathways of Epstein-Barr virus-encoded latent membrane protein 2A (LMP2A) in latency and cancer.
    Pang MF; Lin KW; Peh SC
    Cell Mol Biol Lett; 2009; 14(2):222-47. PubMed ID: 19082921
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PY motifs of Epstein-Barr virus LMP2A regulate protein stability and phosphorylation of LMP2A-associated proteins.
    Ikeda M; Ikeda A; Longnecker R
    J Virol; 2001 Jun; 75(12):5711-8. PubMed ID: 11356981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epstein-Barr Virus Latent Membrane Protein 2A (LMP2A) enhances IL-10 production through the activation of Bruton's tyrosine kinase and STAT3.
    Incrocci R; Barse L; Stone A; Vagvala S; Montesano M; Subramaniam V; Swanson-Mungerson M
    Virology; 2017 Jan; 500():96-102. PubMed ID: 27792904
    [TBL] [Abstract][Full Text] [Related]  

  • 9. c-Myc Represses Transcription of Epstein-Barr Virus Latent Membrane Protein 1 Early after Primary B Cell Infection.
    Price AM; Messinger JE; Luftig MA
    J Virol; 2018 Jan; 92(2):. PubMed ID: 29118124
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epstein-Barr virus latent membrane protein 2A (LMP2A) employs the SLP-65 signaling module.
    Engels N; Merchant M; Pappu R; Chan AC; Longnecker R; Wienands J
    J Exp Med; 2001 Aug; 194(3):255-64. PubMed ID: 11489945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epstein-Barr virus latency: LMP2, a regulator or means for Epstein-Barr virus persistence?
    Longnecker R
    Adv Cancer Res; 2000; 79():175-200. PubMed ID: 10818681
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epstein-Barr virus LMP2A reduces hyperactivation induced by LMP1 to restore normal B cell phenotype in transgenic mice.
    Vrazo AC; Chauchard M; Raab-Traub N; Longnecker R
    PLoS Pathog; 2012; 8(4):e1002662. PubMed ID: 22536156
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of Epstein-Barr virus-encoded latent membrane protein 2A on virus-induced immortalization and virus activation.
    Konishi K; Maruo S; Kato H; Takada K
    J Gen Virol; 2001 Jun; 82(Pt 6):1451-1456. PubMed ID: 11369890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of the Epstein-Barr virus latent membrane protein 2A on B cell function.
    Merchant M; Swart R; Katzman RB; Ikeda M; Ikeda A; Longnecker R; Dykstra ML; Pierce SK
    Int Rev Immunol; 2001; 20(6):805-35. PubMed ID: 11913951
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tyrosine 112 of latent membrane protein 2A is essential for protein tyrosine kinase loading and regulation of Epstein-Barr virus latency.
    Fruehling S; Swart R; Dolwick KM; Kremmer E; Longnecker R
    J Virol; 1998 Oct; 72(10):7796-806. PubMed ID: 9733815
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of latent membrane protein 2A (LMP2A) specific targets for treatment and eradication of Epstein-Barr virus (EBV)-associated diseases.
    Swanson-Mungerson M; Ikeda M; Lev L; Longnecker R; Portis T
    J Antimicrob Chemother; 2003 Aug; 52(2):152-4. PubMed ID: 12837743
    [No Abstract]   [Full Text] [Related]  

  • 17. Epstein-Barr virus LMP2A suppresses MHC class II expression by regulating the B-cell transcription factors E47 and PU.1.
    Lin JH; Lin JY; Chou YC; Chen MR; Yeh TH; Lin CW; Lin SJ; Tsai CH
    Blood; 2015 Apr; 125(14):2228-38. PubMed ID: 25631773
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Latent Membrane Protein 1 (LMP1) and LMP2A Collaborate To Promote Epstein-Barr Virus-Induced B Cell Lymphomas in a Cord Blood-Humanized Mouse Model but Are Not Essential.
    Ma SD; Tsai MH; Romero-Masters JC; Ranheim EA; Huebner SM; Bristol JA; Delecluse HJ; Kenney SC
    J Virol; 2017 Apr; 91(7):. PubMed ID: 28077657
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Latent Membrane Protein 2 (LMP2).
    Cen O; Longnecker R
    Curr Top Microbiol Immunol; 2015; 391():151-80. PubMed ID: 26428374
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LMP1-Induced Sumoylation Influences the Maintenance of Epstein-Barr Virus Latency through KAP1.
    Bentz GL; Moss CR; Whitehurst CB; Moody CA; Pagano JS
    J Virol; 2015 Aug; 89(15):7465-77. PubMed ID: 25948750
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.